Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.
Zsófia M SztupinszkiMiklos DiossyJudit BörcsökAurel ProszNanna CorneliusMaj K KjeldsenMansoor R MirzaZoltan SzallasiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
When WES data are available, methods that quantify only large chromosomal alterations such as the HRD score and HRDetect that captures a wider array of HRD-induced genomic aberrations are equally efficient identifying HRD ovarian cancer cases.